Lipid Disorders
5
1
1
3
Key Insights
Highlights
Success Rate
75% trial completion
Treatment Research
3 treatments under study, led by Atorvastatin And Fenofibrate
Research Leaders
5 sponsors active, led by National Heart Foundation, Australia
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
20.0%
1 terminated out of 5 trials
75.0%
-11.6% vs benchmark
40%
2 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (5)
Genes Involved in Lipid Disorders
Lipoprotein Interactions and Platelet Function in Healthy Individuals and Those With Lipid Disorders
A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers
Regulation of Lipoprotein Transport in Metabolic Syndrome
Pharmacological Regulation of Fat Transport in Metabolic Syndrome
Research Network
Common Treatments
- Atorvastatin And Fenofibrate1
- Gw5015161
- Zyt11
Active Sponsors
- National Heart Foundation, Australia2
- The University of Western Australia2
- Zydus Lifesciences Limited1
- The Miriam Hospital1
- National Heart, Lung, and Blood Institute (NHLBI)1
Top Investigators
National Heart, Lung, and Blood Institute (NHLBI)
The University of Western Australia
Related Conditions
- Obesity3
- Cardiovascular Disease2
- Hypertriglyceridemia1